Winners in patient vs patent war
India is a major live market to test a question that global drugmakers regularly ask. Once a blockbuster medicine loses exclusivity due to the expiry of its patent, does the original brand survive due to the patients’ trust, or does competition swamp it out of the marketplace? Yesterday, on March 20, a key molecule behind Novo Nordisk’s diabetes-weight reduction drug, lost patent protection in India. As expected, 40-50 Indian firms are ready to launch their versions, with prices expected to come down by 80-90 per cent, from `11,000 to `1,500-2,500.
While this trend will fuel worries about overprescription and misuse, there is no denying that in a price-sensitive market, it will considerably widen the patients’ base. However, in a branded-generics combined market, post-patent developments are shaped only by price, but by doctors’ confidence, patient familiarity, firm’s reputation, marketing reach, and quality assurances. This may give this story a new tension. The patent is gone. Will the patients move on, and embrace the competitors? Novo Nordisk states that it is unwilling to take part in the expected price war, as patients, on the advice of doctors, will pay a price for brand assurance, clinical familiarity, and product trust.
However, there are precedents that the original patent holder may be proved both right and wrong. When Novartis’s diabetes drug went off-patent in 2019, more than 20 generic versions entered the market almost immediately. It was a familiar post-patent pattern: Fast entry, price compression, and a molecule pulled into the brutal competitive price grinder. Despite medical advice, word-of-mouth, and brand recall, patients seek cheaper versions. The medical fraternity can veer away. In another case, a firm stayed active despite losing out.
What is relevant is that Novo Nordisk’s diabetes drug is not like Novartis’ one. The former is not an oral therapy moving out from the exclusive patented zone to a competitive one. It sits at the intersection of diabetes, obesity, and lifestyle medicine, whose demand is pulled and pushed by celebrity-endorsers because of the weight-reduction results. It is injectable rather than a conventional tablet. It comes with stronger patient’s expectations, greater anxiety around misuse and side effects, and more sensitivity around product authenticity and quality.
In March this year, the drug regulator warned firms against advertising of weight-loss drugs, which underscored how this category is being watched. This is a market in which trust sits with the molecule, device, dosing experience, supply chain, and patients’ confidence. Hence, one may assume that an existing patient hooked on the now off-patented drug may not switch to cheaper versions. Similarly, a doctor, who manages diabetes or obesity patients over a longer term may prefer the original brand for some cohorts. In an injectable category, questions of pen design, titration, training, and support are differentiators.
Yet, Novo Nordisk understands that the future fight will not be won by nostalgia. Although it was against a price war, it slashed the price of one of the drugs by up to 33 per cent. This suggests a careful playbook. Reduce prices to remain relevant vis-à-vis competitors, and preserve premium to keep the brand distinct. It is a classic balancing act. Drop the prices too little, and the drug becomes too expensive and unaffordable. Drop them too much, and you concede that the drug is the same as the others without any differentiators.
But the competition will be intense. Dr Reddy’s reportedly plans a March launch, and hopes to target 12 million injectable pens in the first year, and potentially price the product 50-60 per cent below the original’s version. Two days before the patent expiry, a news agency reported that Zydus and Lupin signed a co-marketing deal for the injections to broaden the distribution rights. Those are not tactical moves. They signal what the next phase of the market may look like. It will not be a two-way fight between a former innovator and copycat.
More likely, the segment will emerge as a dense branded battlefield in which dozens of players compete on price, availability, relationships, and product format. The original patent holder may try to preserve a premium based on familiarity, trust, and other issues. India has the second-largest population of adults with diabetes in the world, and obesity has become a larger commercial and public-health category. The general presumption is that volumes will expand as expensive therapies become affordable. A market that was previously constrained by high prices will become broader, but less profitable for the firms.
This is when this story becomes interesting compared to any other patent-generics one. “Survival” after patent expiry is not a binary condition. The original firm does not need to dominate the market to remain strategically relevant. It may retain premium urban patients. It may become the preferred brand for initiation, even if the patients later drift to lower-cost alternatives. It may hold its ground among specialists, and lose volumes in general practice. It may preserve some segments, like obesity, and cede the others, like diabetes, to the generic competitors. In a chronic-care market, these
gradations matter.
Physician inertia can play a role, especially in the case of stable chronic patients. Another is the reputational advantage attached to known makers in categories where long-term adherence and patient confidence matter. India’s pharma market is intensely price-sensitive, but it is not price-blind. Trust still has a commercial value, especially when therapies are complex, high-profile, or vulnerable to misuse. There are reasons why Novo Nordisk’s strategy may follow the harder rule that patients do matter until there comes a time when they do not.
Either within a year, or over a few years, newcomers with lower prices, strong distribution, and aggressive field execution will put pressure on the original brand. Past experiences show how rapidly the economics can shift once a molecule goes off-patent, even if it takes a while for the process to intensify. In such cases, loyalty proves thinner than expected. This is why India matters in the present case. It is one of the first major markets where the diabetes molecule will move into a post-patent phase, even as the global demand remains intense and high.
What happens in India will offer a live commercial test of a larger industry question, one that has been asked repeatedly. Over the next few quarters, or possibly a few years, the answer will not be found in the labs. It will be visible on the prescription pads, chemist counters, pricing ladders, and patients’ behaviour. The legal monopoly has ended. What remains to be seen is whether the brand legacy survives.
